PAIN CLINIC · MME MONITORING ACTIVE · TOPIC: CHRONIC PAIN & OPIOID THERAPY · REF: CDC / FDA / APS
The Pain Protocol Pain medicine reference · U.S. edition
Pain medicine · Opioid stewardship

Opioids are neither miracle drugs nor villains. They are tools with very specific limits.

Roughly 50 million American adults live with chronic pain, and opioid prescribing has swung from overuse in the 2000s to under-treatment in the 2020s. The evidence-based middle ground is narrower than either extreme: careful selection, low doses where possible, non-opioid therapies first, and structured monitoring when opioids are used.

16 min read
CDC 2022 guideline aligned
MME · conversion · taper
50M+
U.S. adults live with chronic pain — 20 million of them with high-impact chronic pain.
80K
Opioid overdose deaths in the U.S. annually — most now involve illicit fentanyl, not prescribed opioids.
12 wks
Duration of modest benefit typically demonstrated for opioids in chronic non-cancer pain trials.
4×
Overdose risk multiplier at ≥ 100 MME/day compared with 1–20 MME/day.
Section 01 · The problem

Two decades of swings — and the evidence for a middle path.

Opioid prescribing in the United States has followed a whipsaw trajectory. In the 1990s and 2000s, prescribing expanded dramatically, driven by reassurances about low addiction risk and by pressure to treat pain more aggressively. By 2010, enough opioid was being prescribed annually to give every adult in the country a month's supply. The consequences — rising overdose deaths, diversion, and a transition to illicit opioids including fentanyl — took a decade to fully register.

The pendulum then swung toward restriction. In many places, prescribing fell faster than the underlying problem, and patients with legitimate pain were left without adequate treatment, or were tapered abruptly in ways that caused crisis. The CDC's 2022 guideline explicitly acknowledged this harm and revised its approach to emphasize individualized, flexible care over rigid dose thresholds.

What the evidence supports today is narrower than either extreme. For acute pain and cancer pain, opioids remain appropriate when used carefully. For chronic non-cancer pain, the evidence for long-term opioid benefit is modest: randomized trials show small improvements in pain and function over 6 to 12 weeks, but diminishing benefit beyond that, and increasing risk. Non-opioid approaches — physical therapy, cognitive behavioral therapy, specific non-opioid medications, and procedures — are first-line for most chronic pain conditions.

What follows is the practical machinery of safe opioid prescribing: how to measure dose risk, how to compare opioids, how to use adjuncts, when to co-prescribe naloxone, and how to taper when the balance tips toward harm.

Section 02 · Risk stratification

Four MME tiers — and what each one changes.

Dose is one of several risk factors. It is the most measurable, and it is the one that triggers specific clinical actions at defined thresholds.

< 20 MME/day

Low dose

Standard monitoring. Prescribe the smallest effective dose and reassess benefit within 1–4 weeks. Naloxone still indicated if other risk factors are present.

20–49 MME/day

Moderate dose

Increase monitoring frequency. Consider urine drug screens and check the state prescription drug monitoring program at intervals. Reassess benefit vs harm at each visit.

50–89 MME/day

Higher dose — offer naloxone

Offer naloxone to the patient and their household. Reconsider whether benefit outweighs risk. Consider consulting a pain specialist if not already involved.

≥ 90 MME/day

Highest dose — reassess or taper

Carefully justify continued prescribing above this threshold. Consider taper to a lower dose, or referral. Risk of overdose rises steeply above 100 MME/day.

Section 03 · Conversions

Opioid conversion factors — approximate, and always approximate.

Equianalgesic tables convert between opioids for rotation or MME calculation. Cross-tolerance is incomplete, so when rotating opioids, prescribers usually reduce the calculated equivalent dose by 25–50% to avoid overdose.

Opioid MME factor Typical starting Notes
Morphine (oral) 1.0 15–30 mg q4h PRN Reference standard. Extended-release forms should only be used in opioid-tolerant patients.
Oxycodone (oral) 1.5 5–10 mg q6h PRN Most commonly prescribed opioid in the U.S. Many combination products include acetaminophen — watch the total acetaminophen dose.
Hydrocodone (oral) 1.0 5–10 mg q6h PRN Formerly reported as 1.0 but reclassified to 1.0 following the 2013 rescheduling. Combination products contain acetaminophen or ibuprofen.
Hydromorphone (oral) 4.0 2–4 mg q4h PRN Potent; not equivalent to hydrocodone. Confusion between them is a common prescribing error.
Codeine (oral) 0.15 15–60 mg q4h PRN Requires CYP2D6 conversion to morphine; poor metabolizers may not respond, ultra-rapid metabolizers risk toxicity. Avoided in children.
Tramadol (oral) 0.1 50 mg q6h PRN Also affects serotonin and norepinephrine. Seizure risk, serotonin syndrome with SSRIs, and withdrawal if stopped abruptly.
Methadone (oral) Varies 3–12 Specialist use Complex and non-linear conversion. Only prescribers experienced with methadone should rotate to it. QTc monitoring required.
Fentanyl (transdermal) 2.4 per mcg/hr Only opioid-tolerant Absorption increases with heat (fever, hot showers, heating pads) — a cause of overdose. Not for acute or post-operative pain.
Section 04 · Treatment strategy

Non-opioid first, opioid if needed, and always consider the adjuncts.

Most chronic pain — especially back pain, osteoarthritis, and neuropathic pain — responds better to non-opioid therapy as first-line. Opioids may still have a role, but they should be added rather than substituted for other approaches.

Non-opioid options — first-line for most chronic pain
Medication + non-pharmacologic

Acetaminophen (up to 3,000 mg/day from all sources) and NSAIDs (with GI, kidney, and cardiovascular caveats) remain first-line for many pain types. Topical NSAIDs (diclofenac gel) are effective for localized osteoarthritis with minimal systemic exposure.

SNRIs (duloxetine) and gabapentinoids (gabapentin, pregabalin) are first-line for neuropathic pain. TCAs (nortriptyline, amitriptyline) have decades of evidence for neuropathic pain at low doses. Physical therapy and CBT have some of the strongest evidence of any intervention for chronic low back pain.

Examplesacetaminophen · NSAIDs · topical diclofenac · duloxetine · gabapentin · nortriptyline · CBT · PT
Opioids — when other options are insufficient
Lowest effective dose · defined goals

When opioids are used for chronic pain, the principles are consistent: lowest effective dose, immediate-release first, defined functional goals, and a plan for reassessment. "Pain reduction" alone is not a sufficient goal — functional improvement (walking, working, sleeping) is what guides continuation.

Extended-release and long-acting opioids are reserved for opioid-tolerant patients with continuous severe pain. They carry higher overdose risk and are not appropriate for acute pain. Do not combine with benzodiazepines when avoidable — the combination substantially increases respiratory depression and overdose risk.

Exampleshydrocodone · oxycodone · morphine · hydromorphone · tramadol · fentanyl patch
Adjuncts — opioid-sparing when opioids are used
Combine rather than escalate

Adding an adjunct often allows a lower opioid dose for the same pain relief. Acetaminophen scheduled around the clock reduces opioid requirements. NSAIDs, muscle relaxants (short-term), and topical agents all have a role. Ketamine and lidocaine infusions are specialist options for refractory pain.

Cannabinoids are frequently used by patients but have limited high-quality evidence for chronic pain, with modest benefit for neuropathic pain at best. They also interact with opioids and can worsen psychiatric symptoms.

Examplesscheduled acetaminophen · topical lidocaine · cyclobenzaprine (short-term) · ketamine (specialist)
Naloxone — the rescue medication
Offer to every at-risk patient

Naloxone reverses opioid-induced respiratory depression. It is safe, has no abuse potential, and is now available over the counter as Narcan nasal spray in the U.S. It does not reverse overdoses from non-opioid substances, but will not cause harm if given when opioids are not the cause.

Offer naloxone to any patient on ≥ 50 MME/day, any patient on concurrent benzodiazepines, and any patient with a history of substance use disorder. Also offer to household members. Train the household on use — during an overdose, there is no time to read the instructions.

Examplesnaloxone nasal spray (Narcan, generics) · naloxone injection
Section 05 · Tapering

When and how to taper — gradual, individualized, and never abrupt.

Long-term opioid therapy should be reassessed periodically. If benefit has not been demonstrated, or if harms emerge, a gradual taper is the appropriate next step. Abrupt discontinuation after long-term use is dangerous.

A standard taper — dose over time
Illustrative · individualize in practice
90 60 45 30 0 MME Start Month 1 Month 3 Month 6 Month 9 Month 12 -10% -10% -10% paused
1

Discuss and plan together

Explain why taper is being considered and what the plan looks like. Shared decision-making improves success. Set expectations for withdrawal symptoms and how they will be managed.

2

Reduce by 5–10% every 2–4 weeks

For patients on long-term therapy. Slower tapers are appropriate for those on opioids for years. Pause the taper if withdrawal symptoms or pain worsen significantly.

3

Provide support through withdrawal

Clonidine for autonomic symptoms, antiemetics, and short-term NSAIDs. Non-opioid pain management should be in place before and during the taper.

4

If taper fails, reassess — do not abandon

If a patient cannot taper despite real effort, do not simply discharge them from care — abrupt discontinuation is dangerous. Reassess dose, consider buprenorphine as an alternative, and involve a specialist.

The 2019 case that changed practice. After abrupt discontinuation of opioids became common in response to the 2016 CDC guideline, reports emerged of patients turning to illicit opioids, experiencing severe withdrawal, and in some cases dying by suicide. The 2022 CDC guideline explicitly warns against abrupt discontinuation and emphasizes that tapering is voluntary, gradual, and patient-centered. Prescribers who cannot manage the taper safely should refer, not abandon.

Section 06 · Overdose response

Recognizing and reversing an opioid overdose.

Opioid overdose is a medical emergency. It can happen to someone taking a prescribed dose when combined with a depressant, with a change in metabolism, or during a dose escalation. It is not a moral failure. It is a respiratory event that requires naloxone and 911.

Signs to recognize: pinpoint pupils, slow or absent breathing, blue lips or fingertips, extreme drowsiness or unresponsiveness, choking or gurgling sounds, and a limp body. When in doubt, treat it as an overdose — naloxone will not harm someone who is not overdosing on opioids.

What to do: call 911, give naloxone (nasal or injection), stay with the person, and if there is no breathing, begin rescue breathing or CPR. Naloxone wears off in 30 to 90 minutes — the person must still be evaluated, because re-sedation can occur. Many states have Good Samaritan laws that protect people who call 911 for an overdose.

Naloxone is available over the counter in the United States as Narcan nasal spray and as generics, without a prescription, at most pharmacies. Community distribution programs also provide it for free in many cities. If you or someone in your household takes opioids — prescribed or otherwise — having naloxone on hand is one of the single most effective harm-reduction measures available.

Section 07 · What to watch for

Signs that the current regimen is not safe or is not working.

Reassess now

If any of these appear, contact the prescriber rather than adjusting on your own.

Taking more than prescribed, or running out early. Both are signals that either the dose is inadequate or the medication is not the right treatment. Neither is solved by requesting a higher dose in isolation.
Sedation that interferes with daily function, confusion, or slurred speech. Suggests over-sedation — reduce dose and reassess. Call emergency services for slow breathing or unresponsiveness.
Concurrent use of benzodiazepines, alcohol, or sleep medications. Multiplies respiratory depression risk substantially. This combination should prompt a taper of at least one agent and naloxone co-prescribing.
New depression, hopelessness, or thoughts of self-harm during a taper. Opioid taper has been associated with increased suicide risk. Contact a clinician or call/text 988 (U.S. Suicide & Crisis Lifeline) immediately. Do not push through alone.
New or worsening pain in a different location, or pain that has changed character. May indicate a new problem rather than a need for more opioid. Evaluation should precede any dose change.
Signs of opioid use disorder — craving, compulsive use, loss of control, using despite harm. This is a medical condition, not a personal failing. Buprenorphine and methadone are highly effective treatments and can be prescribed by primary care.
Section 08 · Access & affordability

Opioid medication is cheap. The price still varies.

Most prescribed opioids are available as low-cost generics in the United States. Hydrocodone-acetaminophen, oxycodone, morphine, and tramadol are all manufactured by multiple companies and priced well below their original brand versions. Naloxone is now available over the counter and as generics. Buprenorphine — one of the most effective treatments for opioid use disorder — has a generic form and is covered by most insurance plans and Medicare. Methadone for opioid use disorder is dispensed through federally regulated opioid treatment programs.

What still varies at the pharmacy counter: the same generic tablet can cost several times more at one licensed pharmacy than another. Controlled substances have additional legal restrictions on refills and transfers, but the pricing differences between pharmacies remain substantial. A live prescription price comparison shows the current range in about two minutes, and the same logic applies to every generic on a patient's list. If you are filling an online refill for the first time, the process is documented step by step in this how to order prescriptions online guide — prescription first, licensed seller second, small first order third.

One caveat specific to controlled substances: many online pharmacies do not dispense them, either because of state law or business policy. Schedule II opioids cannot be filled by most online sellers. This is expected — it does not indicate a problem with the seller. Legitimate local pharmacies and chain pharmacies with a physical presence remain the standard for controlled substances.

Before filling from any seller — online or local — verify them. A working VIPPS seal that resolves to a live NABP record, a real U.S. street address, and a prescription requirement that cannot be waived. A transparency page like this one about Metformin4You is a reasonable example of the standard to expect.

Section 09 · Questions

Five asked most often at the pain clinic.

Q·01 What is an MME and why does it matter? +
MME stands for morphine milligram equivalent. It is a standardized way to express the total daily dose of any opioid in terms of morphine, so that different opioids can be compared. Higher MME doses (particularly above 90 MME/day) are associated with substantially higher risk of overdose. The CDC recommends caution above 50 MME/day and careful reassessment or specialist involvement above 90 MME/day.
Q·02 What is the difference between physical dependence and addiction? +
Physical dependence is a predictable physiological adaptation — stopping an opioid abruptly causes withdrawal symptoms. It is expected in anyone who takes opioids regularly for more than a few days. Addiction is a behavioral disorder characterized by craving, compulsive use, loss of control, and continued use despite harm. Many patients with chronic pain are physically dependent without being addicted.
Q·03 When should naloxone be prescribed alongside opioids? +
CDC guidelines recommend offering naloxone to patients on 50 MME/day or higher, patients with a history of substance use disorder, patients on concurrent benzodiazepines, and patients with other risk factors for overdose. Naloxone is a rescue medication for opioid overdose and is safe, effective, and increasingly available over the counter.
Q·04 How is an opioid taper done safely? +
Tapers should be gradual and individualized. A common approach is to reduce by 5 to 10 percent of the total daily dose every 2 to 4 weeks for patients on long-term therapy, with slower tapers (or pauses) if withdrawal symptoms or pain worsen. Abrupt discontinuation after long-term use is dangerous and can cause severe withdrawal, crisis, and in some cases suicide risk.
Q·05 Do opioids actually work for chronic pain? +
The evidence for long-term opioid effectiveness in chronic non-cancer pain is modest. Trials show modest short-term benefit for pain and function, but the benefits diminish over months, and there is little evidence of sustained improvement beyond 12 weeks. Non-opioid approaches — physical therapy, cognitive behavioral therapy, topical agents, and specific non-opioid medications — are first-line for most chronic pain conditions.
◆ Sources & Verification
This reference is aligned with public clinical guidance from the CDC Clinical Practice Guideline for Prescribing Opioids for Pain (2022), the U.S. Food and Drug Administration's Opioid Medications resource center, and the Substance Abuse and Mental Health Services Administration (SAMHSA) medication for opioid use disorder resources. Drug-label information draws on the National Library of Medicine's DailyMed database and MedlinePlus. Pharmacy verification follows the NABP VIPPS program. Opioid overdose reversal resources and free naloxone are available through CDC Stop Overdose.
◆ Before the next refill

Pain management is complex. Prescription pricing does not have to be.

Most pain medications are available as low-cost generics, and the same tablet can cost several times more at one licensed pharmacy than another. A two-minute comparison across licensed U.S. sellers is a useful habit to build — though controlled substances have additional restrictions on where they can be filled. Begin with the current Metformin price comparison as a live demonstration of how wide the spread runs.

Open the price comparison